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Abstract 
 
Background and purpose: Parkinson's disease (PD) is a prevalent movement disorder in 
elderly with progressive motor complications due to antioxidant defense system deficiency and 
accumulation of degraded proteins in dopaminergic neurons of midbrain. Ginkgolide is biologically 
active terpenic lactones as a polyphenol, with potent antioxidant and anti-inflammatory properties. The 
present study aimed to evaluate the neuroprotective effects of Ginkgolide in 6-hydroxydopamine (6-
OHDA) rat model of PD. 
Materials and methods: Intrastriatal 6-OHDA-parkinson’s disease rat model was pretreated 
with Ginkgolide at 50 mg/kg/day for 4 weeks. Apomorphine-induced rotation test was applied to evaluate 
the neuroprotective effects of Ginkgolide. In addition, the antioxidant effects of Ginkgolide were assessed 
by analyzing the levels of thiobarbituric acid reactive substances (TBARS), Glutathione-S-transferase 
(GST), reactive oxygen species (ROS) homovanillic acid (HVA), and dopamine (DA). 
Results: Ginkgolide pretreatment led to reduced nigral and striatal TBARS, and ROS and 
increased the levels of GST, HVA, and DA. Meanwhile, Ginkgolide attenuates apomorphine-induced 
rotational bias and reduced contra-lateral rotation in Ginkgolide treatment group. 
Conclusion: These findings indicated the neuroprotective potential of Ginkgolide in 6- OHDA 
rat model of PD via amelioration of oxidative stress. 
 
Keywords: Parkinson’s disease, 6-hydroxydopamine, ginkgolide, oxidative stress 
 
J Mazandaran Univ Med Sci 2019; 28 (170): 11-21 (Persian). 
 
 
 
 
* Corresponding Author: Shahram Darabi - Cellular and Molecular Research Center, Qazvin University of Medical 
Sciences, Qazvin, Iran (E-mail: shahram2005d@yahoo.com) 
D
ow
nl
oa
de
d 
fro
m
 jm
um
s.m
az
um
s.a
c.i
r a
t 1
0:3
2 +
04
30
 on
 W
ed
ne
sd
ay
 A
ug
us
t 1
4th
 20
19
